Dori Pelled
Geschäftsführer bei Imel Biotherapeutics, Inc.
Profil
Dori Pelled is currently the Chief Operating Officer at Imel Biotherapeutics, Inc. He previously worked as the CTO & Director-Clinical Research at Enzymotec Ltd.
and as the Vice President-Operations at Eloxx Pharmaceuticals, Inc. He received his undergraduate and graduate degrees from Tel-Aviv University and his doctorate from Weizmann Institute of Science.
Aktive Positionen von Dori Pelled
Unternehmen | Position | Beginn |
---|---|---|
Imel Biotherapeutics, Inc.
Imel Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Imel Biotherapeutics, Inc. develops treatment for mitochondrial disease. The company was founded on February 21, 2019 and is headquartered in United States. | Geschäftsführer | 01.03.2019 |
Ehemalige bekannte Positionen von Dori Pelled
Unternehmen | Position | Ende |
---|---|---|
ELOXX PHARMACEUTICALS, INC. | Geschäftsführer | 25.06.2018 |
ENZYMOTEC LTD. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Dori Pelled
Tel-Aviv University | Graduate Degree |
Weizmann Institute of Science | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ELOXX PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Enzymotec Ltd.
Enzymotec Ltd. BiotechnologyHealth Technology Enzymotec Ltd. develops and manufactures bio functional ingredients for health needs. The company was founded on March 8, 1998 and is headquartered in Migdal HaEmeq, Israel. | Health Technology |
Imel Biotherapeutics, Inc.
Imel Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Imel Biotherapeutics, Inc. develops treatment for mitochondrial disease. The company was founded on February 21, 2019 and is headquartered in United States. | Commercial Services |